Company news
Disc Medicine, Inc. (NASDAQ:IRON) news
Disc Medicine, Inc. news releases on 6ix. Latest, Feb 28, 2022: Gemini Therapeutics Provides Corporate Update
Press releases — page 3
Gemini Therapeutics Provides Corporate Update
February 27, 2022
Gemini Therapeutics Provides GEM103 Program Update
January 9, 2022
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 14, 2021
Gemini Therapeutics Announces Poster Presentation at AAO 2021
November 11, 2021
Gemini Therapeutics to Participate in Upcoming Investor Conferences
November 10, 2021
Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
October 18, 2021
Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 13, 2021
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
October 4, 2021
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
September 9, 2021
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
September 8, 2021
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
August 29, 2021
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
June 21, 2021
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 25, 2021
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 12, 2021
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
May 12, 2021
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
May 2, 2021
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 30, 2021
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 12, 2021
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 11, 2021
Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
March 28, 2021
Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic Variants
February 9, 2021
Gemini Therapeutics Appoints Brian Piekos as Chief Financial Officer
February 8, 2021